![Alex Trebeks Cbd Gummies: A Practical Look At The Celebrity Linked Trend [zydRGYwbdTp]](https://i0.wp.com/cedclinic.com/wp-content/uploads/2026/06/ced-pexels-5469158.jpg?resize=150%2C150&ssl=1 "Alex Trebeks Cbd Gummies: A Practical Look At The Celebrity Linked Trend 26")
![Cbd Gummies Supplement: A Practical Guide For Everyday Wellness [QHSCtaspdLc]](https://i0.wp.com/cedclinic.com/wp-content/uploads/2026/06/ced-pexels-7883504.jpg?resize=150%2C150&ssl=1 "Cbd Gummies Supplement: A Practical Guide For Everyday Wellness 27")
GLP-1 Drugs and Cervical Fusion: What Conflicting
GLP-1 cervical fusion outcomes were synthesized across 12 retrospective cohorts. Estimates differed by procedure and dataset, and the overall model showed extreme heterogeneity. The evidence does not establish a protective or harmful class-wide effect.
Antidiabetic Drugs and Parkinson’s Risk: What a Nine-Cohort Meta-Analysis Found
antidiabetic drugs Parkinson's risk: Antidiabetic drugs and Parkinson's risk were compared across nine observational cohorts totaling 712,287 patients. No class difference was statistically significant, although GLP-1 and SGLT2 therapies had favorable…
Semaglutide and Cognition in Psychiatric Care: What a 13,007-Patient Cohort Found
semaglutide cognition psychiatric cohort: In a retrospective cohort of 13,007 adults with psychiatric diagnoses, semaglutide initiation was associated with fewer clinician-recorded cognitive signs over 12 months than no antidiabetic treatment, glipizide,…
GLP-1 Drugs and Intracranial Hypertension: What a Low-Certainty Meta-Analysis Found
GLP-1 idiopathic intracranial hypertension evidence was synthesized across eight studies and 13,243 patients. Papilledema, headache, visual, and refractory-disease outcomes favored GLP-1 exposure. Observational dominance, confounding, and heterogeneity…
GLP-1 Plus SGLT2 Therapy: What an Exploratory Cardiorenal Meta-Analysis Found
GLP-1 SGLT2 combination cardiorenal outcomes were examined across 16 randomized trial datasets. Combination use ranked favorably for cardiovascular and kidney outcomes. The mostly nonrandomized subgroup comparisons make the findings hypothesis-generating…
Dulaglutide vs Insulin in Adolescents With Thalassaemia-Related Diabetes
In a 24-week randomized trial, dulaglutide in thalassaemia-related adolescent diabetes improved glucose variability and metabolic outcomes compared to basal-bolus insulin. This study involved 80 adolescents with transfusion-dependent beta-thalassaemia…
Once-Weekly IcoSema for Type 2 Diabetes: What COMBINE 4 Found
IcoSema COMBINE 4 trial: Once-weekly IcoSema lowered HbA1c and produced a more favorable body-weight change than daily insulin glargine over 40 weeks. Clinically significant or severe hypoglycemia was less frequent, while gastrointestinal disorders were…
Oral Semaglutide for Alcohol Use Disorder: What a New Randomized Trial Found
A phase 2 oral semaglutide alcohol use disorder randomized trial tested 50 adults with moderate to severe alcohol use disorder. The primary craving endpoint was not significantly improved, but several secondary drinking outcomes favored semaglutide.…
Oral VCT220 Phase II Trial: GLP-1 Receptor Agonist for Obesity
A 16-week phase II oral nonpeptide GLP-1 receptor agonist obesity trial found oral VCT220 produced significantly greater weight loss than placebo in 250 adults. The study showed mainly mild to moderate gastrointestinal adverse events but was limited by…
Cannabis Use With GLP-1 Therapy: What a Diabetes Cohort Found
Cannabis and GLP-1 therapy were examined in a matched cohort of 8,234 adults with type 2 diabetes. Cannabis-related diagnosis codes were associated with higher mortality, cardiovascular events, and kidney events. The retrospective design raises a safety…